[Combination of anti-EGFR and anti-HER2 antibodies: hope in pancreatic cancer treatment].
Unresectable pancreatic cancer is still an extremely dismal prognosis. The conventional therapy using chemotherapy has no real effect on survival and new treatments are needed. EGFR and HER2 have been reported to be implicated and upregulated in pancreatic cancer tumorigenesis. The use of monoclonal antibodies (mAb) targeting these two receptors seems a relevant strategy for a new therapy. In a pre-clinical study, we demonstrated the therapeutic effect of the combination of two humanized Ab used in clinic, trastuzumab (Ab anti-HER2) and matuzumab (Ab anti-EGFR) in vivo in different carcinoma types. This Ab combination induced an important tumoral growth delay associated with some complete responses in two pancreatic carcinoma models expressing low HER2 level and in an ovarian model. Following all these results, a clinical trial is planned in pancreatic cancer.
Larbouret
Christel
C
Centre de recherche en cancérologie de Montpellier (CRCM), Inserm U860 Immunociblage et radiobiologie en oncologie, Université Montpellier 1. clarbouret@valdorel.fnclcc.fr
Robert
Bruno
B
Teulon
Isabelle
I
Assénat
Eric
E
Azria
David
D
Pèlegrin
André
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C520777:matuzumab